ARTICLE | Clinical News
NN9925: Development discontinued
February 7, 2011 8:00 AM UTC
Novo Nordisk disclosed in its 4Q10 earnings that it discontinued development of NN9925 due to insufficient bioavailability. NN9925, which uses GIPET technology from Merrion, was in Phase I testing to ...